Idinvest Partners and Kurma Life Sciences Partners Celebrate Prosensa IPO

Dutch biotechnology company Prosensa Holding has started its first trading day on the Nasdaq New York, US. Prosensa is the second Idinvest portfolio company completing a market listing this year. Earlier in 2013, Erytech Pharma, a French company specialized in innovative therapeutic approach for cancers was admitted on NYSE Euronext Paris.

PRESS RELEASE

On Friday June 28th, Prosensa Holding B.V. (Prosensa) initiated its first trading day on the Nasdaq New York, US. Prosensa is the second Idinvest Biotech portfolio company completing a market listing this year. Earlier in 2013, Erytech Pharma, a French company specialized in innovative therapeutic approach for cancers was admitted on NYSE Euronext Paris.

Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.
Prosensa announced On Thursday June 27th, the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share corresponding to a $442M company market capitalization.

After the first trading day, Prosensa’s shares were up 48,08%, valuing the company at $720M.

Citigate Dewe Rogerson
Paris Office
18 rue de Londres – 75009 Paris
Tel +33 1 53 32 78 94
Mob +33 6 66 58 84 28
Fax +33 1 53 32 78 96